{"Hepatocellular": [0], "carcinoma": [1], "(HCC)": [2], "is": [3, 11, 19], "a": [4, 8, 46, 73], "prevalent": [5], "disease": [6], "with": [7, 37, 138, 152], "progression": [9], "that": [10], "modulated": [12], "by": [13], "the": [14, 22, 51, 54, 59, 68, 79, 118, 131, 134, 142, 161, 183, 193, 205, 216, 226, 233], "immune": [15, 93], "system.": [16], "Systemic": [17], "therapy": [18, 75], "used": [20, 86], "in": [21, 45, 89, 113, 165, 173, 190, 223], "advanced": [23], "stage": [24], "and": [25, 50, 58, 83, 120, 141, 167, 192, 230, 232], "until": [26], "2017": [27], "consisted": [28], "only": [29], "of": [30, 48, 53, 70, 122, 130, 144, 186, 207, 219, 228], "antiangiogenic": [31], "tyrosine": [32], "kinase": [33], "inhibitors": [34, 39], "(TKIs).": [35], "Immunotherapy": [36], "checkpoint": [38, 115], "has": [40, 63], "shown": [41], "strong": [42], "anti-tumour": [43], "activity": [44], "subset": [47], "patients": [49, 137], "combination": [52], "anti-PDL1": [55], "antibody": [56, 61], "atezolizumab": [57], "VEGF-neutralizing": [60], "bevacizumab": [62], "or": [64, 101, 148, 155], "will": [65], "soon": [66], "become": [67], "standard": [69], "care": [71], "as": [72, 96, 160], "first-line": [74], "for": [76, 204], "HCC,": [77], "whereas": [78], "anti-PD1": [80], "agents": [81], "nivolumab": [82], "pembrolizumab": [84], "are": [85, 117, 158, 169], "after": [87], "TKIs": [88], "several": [90], "regions.": [91], "Other": [92], "strategies": [94, 195, 235], "such": [95], "adoptive": [97], "T-cell": [98], "transfer,": [99], "vaccination": [100], "virotherapy": [102], "have": [103], "not": [104], "yet": [105], "demonstrated": [106], "consistent": [107], "clinical": [108, 175, 217], "activity.": [109], "Major": [110], "unmet": [111], "challenges": [112], "HCC": [114, 166, 191], "immunotherapy": [116], "discovery": [119, 143], "validation": [121], "predictive": [123], "biomarkers,": [124], "advancing": [125], "treatment": [126, 135, 206], "to": [127, 136], "earlier": [128], "stages": [129], "disease,": [132], "applying": [133], "liver": [139], "dysfunction": [140], "more": [145], "effective": [146, 202], "combinatorial": [147], "sequential": [149], "approaches.": [150], "Combinations": [151], "other": [153], "systemic": [154], "local": [156], "treatments": [157], "perceived": [159], "most": [162], "promising": [163], "opportunities": [164], "some": [168], "already": [170], "under": [171, 196, 236], "evaluation": [172], "large-scale": [174], "trials.": [176], "This": [177, 210], "Review": [178, 211], "provides": [179, 212], "up-to-date": [180, 213], "information": [181, 214], "on": [182, 215], "best": [184], "use": [185, 218], "currently": [187, 220], "available": [188, 221], "immunotherapies": [189, 222], "therapeutic": [194, 234], "development.": [197, 237], "Immunotherapeutic": [198], "interventions": [199], "might": [200], "be": [201], "tools": [203], "hepatocellular": [208, 224], "carcinoma.": [209], "carcinoma,": [225], "mechanisms": [227], "response": [229], "resistance,": [231]}